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ABSTRACT 
Producing safe products is a core goal of all medical device manufacturers and sterility assurance is a key component in achieving that 
goal.  Many single use medical devices are terminally sterilized by ethylene oxide or radiation methods such as gamma or e-beam.  The FDA and 
other regulatory bodies requiring that the sterilization process be validated and these validations typically require a bioburden and sterility 
testing.  Sterility testing and bioburden testing are also performed on devices as part of routine quality control. By conducting this test on 
medical device we can assure the in-house sterility; during production, packaging (primary and secondary) and dispatch. To avoid the any error 
or contamination attacks on the product. 
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1. Introduction 
Medical Devices types 
a. Intra uterine devices1 
b. Female sterilization devices1 
1.1 Intrauterine devices2 
Intrauterine device is a small contraceptive device, often 'T'-
shaped, often containing either copper or levonorgestrel, 
which is inserted into the uterus. They are one form of long-
acting reversible contraception which is the most effective 
types of reversible birth control. Failure rates with the 
copper IUD is about 0.8% while the levonorgestrel IUD has a 
failure rate of 0.2% in the first year of use. Among types of 
birth control they, along with birth control implants, result 
in the greatest satisfaction among users. 2 As of 2007, IUDs 
are the most widely used form of reversible contraception, 
with more than 180 million users worldwide. Intrauterine 
device definition lies in its main principle of work that IUD 
simply does not allow the egg to grow, i.e. to attach to the 
uterus, and thus the pregnancy does not occur. In addition, 
these products are made of copper that contributes to the 
production of liquid which has a spermicidal effect. Copper 
intrauterine devices can serve up to 10 years. 3Copper IUDs 
primarily work by disrupting sperm mobility and damaging 
sperm so that they are prevented from joining with an egg. 
Copper acts as a spermicidal within the uterus, increasing 
levels of copper ions, prostaglandins, and white blood cells 
within the uterine and tubal fluids. The increased copper 
ions in the cervical mucus inhibit the sperm's motility and 
viability, preventing sperm from travelling through the 
cervical mucus, or destroying it as it passes through. Copper 
can also alter the endometrial lining, but studies show that 
this alteration can prevent implantation, but not disrupt 
implantation. Copper IUDs have a first year failure rate 
ranging from 0.1 to 2.2%. Most copper IUDs have a plastic T-
shaped frame that is wound around with pure electrolytic 
copper wire and/or has copper collars (sleeves). The arms of 
the frame hold the IUD in place near the top of the uterus. 
The Paragard TCu 380A measures 32 mm (1.26") 
horizontally (top of the T), and 36 mm (1.42") vertically (leg 
of the T). Copper IUDs are becoming increasingly popular 
because they are more resistant to corrosion. 4 In the 
"Eurogine Gold T IUD, which is made in Spain, there is a gold 
core, which further prevents the copper from fragmenting or 
corroding. Goldring Medusa is a differently-shaped German 
version of the Gold T. Another form of AuCu IUD is called 
Goldlily which is made by the Hungarian company, Radelkis. 
Goldlily consists of a layer of copper wires wrapped around 
an original layer of gold wires, and it provides 
electrochemical protection in addition to ionic protection. 
Silver IUDs alsoexist. Radelkis also makes Silverlily, which is 
similar to Goldlily, and Goldring Medusa is available in an 
AgCu version as well. Nova-T 380 contains a strengthening 
silver core, but does not incorporate silver ions themselves 
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to provide electrochemical protection. Other shapes of IUD 
include the so-called U-shaped IUDs, such as the Load and 
Multi load, and the frameless IUD that holds several hollow 
cylindrical minuscule copper beads. It is held in place by a 
suture (knot) to the fundus of the uterus. It is mainly 
available in China, Europe, and Germany, although some 
clinics in Canada can provide it. A framed copper IUD called 
the IUB SCu300A coils during deployment to form a three 
dimensional spherical shape and is based on a shape 
memory alloy core. Advantages of the copper IUD include its 
ability to provide emergency contraception up to five days 
after unprotected sex. It is the most effective form of 
emergency contraception available. It works by preventing 
fertilization or implantation; however does not affect 
already implanted embryos. It contains no hormones, so it 
can be used while breast feeding, and fertility returns 
quickly after removal. Copper IUDs are also available in a 
wider range of sizes and shapes than hormonal IUDs. 5 
Disadvantages include the possibility of heavier menstrual 
periods and more painful cramps. In addition to copper, 
noble metal and progestrogen IUDs, patients in China can get 
copper IUDs with indomethacin. This non-hormonal 
compound reduces the severity of menstrual bleeding, and 
these coils are popular. For women who have such a shape 
of the uterus that it's inconvenient to use the classical IUD 
like "the letter "T", there were created birth control 
intrauterine device with the semi-oval shape with some 
projections. 6 It is difficult to say what kind of intrauterine 
device is the best one, because it is always selected together 
with a doctor and only a health professional can define 
intrauterine device that will be the most suitable for a 
woman. For some women there are quite suitable IUDs with 
silver in a small amount, it has anti- inflammatory effects, 
and someone even chooses IUDs with some gold. 3, 6, 9 
            Types of Intra uterine devices: 
A. Copper T 380A  
It consists of T- shaped body, made from polyethylene 
compounded with barium sulphate, which bears a coil of 
copper wire (99.99 % pure) on its arm, 2 copper sleeves 
(99.99 %) one on each of the horizontal arm and 2 
monofilament threads tied with the bottom of the vertical 
arm. This whole assembly is called Cu T 380 A and remains 
in the body. Other components like Insertion tube, Solid Rod, 
Flange and Arm folder are assist devices used for insertion 
purpose. All the components are packaged in an individual 
pouch. The pouch is then sterilized can be stored for a long 
term. 7, 8, 10 
B. Copper T 380 
A was invented by the population council, USA. The 
population council developed its manufactured 
specification and submitted New Drugs Application NDA 
18-650 to US FDA and got permission for marketing in the 
year 1984. The manufacturing specification provided by 
The Population Council became guideline for manufacturer 
world over. 9, 11, 13 
Mechanism of Action Copper bearing IUDs works primarily 
by causing chemical changes that prevent fertilization. 
Studies show that the copper IUD effectively interrupts the 
reproductive process before implantation and pregnancy. It 
does not act by initiating an abortion. In addition to the 
contraceptive effect of a foreign body in the uterus, the 
Copper T380A functions by way of continuous release of 
copper ions into the uterine fluids. This interferes with some 
enzymatic functions, immobilizes sperm cells and inhibits 
fertilization. In addition, growth and development of the 
ovum, tubal function and implantation are inhibited and the 
biochemical environment of the uterus is ahead. 9, 12, 14 
C. Cu 375  
Cu 375 consists of a U-shaped body, made from 
polyethylene compounded with barium sulphate which 
bears a coil of copper wire (99.99 % pure) on its vertical 
arm and two monofilament nylon threads tied to the 
bottom of the vertical arm.  The vertical arm length is 29 
mm only instead of 35 mm in Cu 375. The width is same i.e. 
18mm. Copper wire of 0.4 mm diameter is wound 41 turns 
on the vertical arm to achieve a surface area of Copper 375 
sq mm. These components U-frame, copper wire nylon 
threads remain inside the body. Shelf life- 4 years effective 
use life- 5 years, from insertion. 14, 15, 16 
D. Effects of Copper  
Cu375 has copper as an integral part. Copper is released in 
the uterine cavity, on a continuous basis, during the lifetime 
of the device. Studies suggest that the copper acts as a 
medicinal substance and has a role in improving the 
contraceptive efficacy of the device. Additional amounts of 
copper available to the body from the Cu375 may 
precipitate symptoms in women with Wilson’s disease. 9, 11, 
18 
 
Figure 1: Copper T (IUD) 
 
Table 1: Efficacy of the IUD’s 
S.N. Product Life span Shelf life 
1 Copper T 380A 10 years 7 years 
2 Cu 375 5 years 4 years 
 
E. IUDs’ not an Abortifacient 
It is important to understand that the IUD is not an 
abortifacient but, rather prevents conception. This position 
is supported by studies that have sought the presence of 
human chorionic gonadotropin in the presence of human 
chorionic gonadotropin in IUD users and compared tubal 
flushing of IUD users with those of non contraceptive 
control subjects. The copper IUD is effective as an EC when 
inserted up to 5 days following intercourse. Copper ions 
released from IUD create an environment that is toxic to 
sperm, preventing fertilization and implantation but not 
disrupt implantation. Because copper IUDs prevent Copper 
can also alter the endometrial lining, but studies show this 
alteration can rather than disrupt pregnancy, they too are 
properly classified as contraceptives, not abortifacient. To 
intended therapeutic and/or diagnostic indication. Copper 
is the only component on the device that gets released 
slowly and therefore the effectiveness of the device, if 
Mehta et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):887-896 
ISSN: 2250-1177                                                                                  [889]                                                                                 CODEN (USA): JDDTAO 
calculated on the basis of the amount of copper released 
from the device, will be several years. 19, 20, 21 
F. Female Sterilization Device 
Surgical sterilization is a safe, highly effective, permanent, 
and convenient form of contraception. The most common 
surgical sterilization procedure for women is called a tubal 
ligation or having the "tubes tied." The fallopian tubes are 
the passageway for the egg to travel from the ovary to the 
uterus. This is where the egg becomes fertilized by the 
male's sperm prior to traveling to the uterus. In tubal 
sterilization, the fallopian tubes are both cut and separated 
or they are sealed shut. This prevents the egg and sperm 
from meeting and thus prevents pregnancy. Tubal ligation 
(incorrectly referred to as tubectomy) is considered major 
surgery requiring the patient to undergo spinal anesthesia. 
It is advised that women should not undergo this surgery if 
they currently have or had a history of bladder cancer. After 
the anesthesia takes effect, a surgeon will make a small 
incision at each side of, but just below the navel in order to 
gain access to each of the two fallopian tubes. With 
traditional tubal ligation, the surgeon severs the tubes, and 
then ties (ligates) them off thereby preventing the travel of 
eggs to theuterus. Other  methods  include  using  clips  or  
rings  to  clamp  them  shut,  or  severing  and cauterizing 
them. Tubal ligation is usually done in a hospital operating-
room setting. This is a permanent sterilization procedure. 
The mechanical properties of tubal ring are such that the 
ring compresses the fallopian tube fully, blocking the 
passage from the ovary to the uterus within minutes. In 
about ten days necrosis is complete and the loop of the tube 
withers away into the abdominal. 19, 22, 23 
2. Tubal Lignation Methods 
2.1 Bipolar coagulation 
The most popular method of laparoscopic female 
sterilization, this method uses electric current to cauterize 
sections of the fallopian tube. 
2.2 Monopolar coagulation 
Less common than bipolar coagulation, mono polar 
coagulation uses electric current to cauterize the tube 
together, but also allows radiating current to further 
damage the tubes as it spreads from the coagulation site. 
Many cases involve a cutting of the tubes after the 
procedure. 19, 20, 21 
2.3 Fimbriectomy 
By removing a portion of the fallopian tube closest to the 
ovary, fimbriectomy eliminates the fallopian tubes ability to 
capture eggs and transfer them to the uterus. 24, 25 
2.4 Irving Procedure 
This procedure calls for placing two ligatures (sutures) 
around the fallopian tube and removing the segment of 
tubing between the ligatures. Then to complete the 
procedure, the ends of the fallopian tubes are connected to 
the back of the uterus and the connective tissue 
respectively. 
2.5 Tubal clip 
The tubal clip (Filshie clip or Hulka clip) technique involves 
the application of a permanent clip onto the fallopian tube. 
Once applied and fastened, the clip disallows movement of 
eggs from the ovary to the uterus. 
2.6 Tubal ring 
The silastic band or tubal ring method involves a doubling 
over of the fallopian tubes and application of a silastic band 
to the tube. 
2.7 Pomeroy tubal ligation 
In this method of tubal ligation, a loop of tube is “strangled” 
with a suture. Usually, the loop is cut and the ends 
cauterized or “burned“. This type of tubal ligation is often 
referred to as cut, tied, and burned. 
2.8 Essure tubal ligation 
In this method of tubal ligation, two small metal and fiber 
coils are placed in the fallopian tubes. After insertion, scar 
tissue forms around the coils, blocking off the fallopian 
tubes and preventing sperm from reaching the egg. 26 
2.9 Adiana tubal ligation 
In this method of tubal ligation, two small silicone pieces 
were placed in the fallopian tubes. During the procedure, 
the health care provider heated a small portion of each 
fallopian tube and then inserted a tiny piece of silicone into 
each tube. After the procedure, scar tissue formed around 
the silicone inserts, blocking off the fallopian tubes and 
preventing sperm from reaching the egg. The procedure can 
no longer be performed due to a lawsuit and judgment 
brought by the company responsible forEssure. 
3. Devices 
3.1 Tubal Rings 27, 28, 29 
The tubal ring (also called the Falope ring, Yoon ring, or Lay 
loop) is a small silastic band placed around a loop of the 
fallopian tube. With this method of tubal ligation, a 2-3 cm 
segment of fallopian tube is drawn inside a narrow cone- 
shaped applicator. The silastic ring (that previously has been 
stretched over the outside of the applicator) is then released 
onto the tubal loop. As the ring contracts due to its elasticity, 
it constricts the base of the loop and blocks the fallopian 
tube. Deprived of its blood supply, the constricted loop is 
replaced with scar tissue, and the remaining healthy tubal  
segments  separate,  similar  to   the Pomeroy   tuballigation 
method. The pregnancy rate is 65% at one year following 
reversal of tubal ring procedures and continues to rise with 
the passage of time. 
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Figure 2: Tubal ring and Plates for Bioburden testing 
 
4. Bioburden 27, 28 
The Bioburden test determines the total number of viable 
microorganisms in or on a medical device, container or 
component. It is performed on any product that requires 
control and/or monitoring of bioburden counts, usually as 
part of a sterilization program. This test acts as an early 
warning system for possible production problems that could 
lead to inadequate sterilization. It is also to calculate the 
necessary dose for effective radiation sterilization and to 
monitor product routinely as a part of quarterly dose audits. 
Bioburden is not a test your product passes or fails- It is 
information. Bioburden is normally defined as the number of 
bacteria living on a surface that has not been sterilized. The 
term is most often used in the context of bioburden testing, 
also known as microbial limit testing, which is performed on 
pharmaceutical products and medical products for quality 
control purposes. Products or components used in the 
pharmaceutical or medical field require control of microbial 
levels during processing and handling. Bioburden or 
microbial limit testing on these products proves that these 
requirements have been met. Bioburden testing for medical 
devices made or used in the USA is governed by Title 21of 
the Code of Federal Regulations and worldwide by ISO 
11737. The aim of bioburden testing is to measure the total 
number of viable micro-organisms (total microbial count) on 
a medical device prior to its final sterilization before 
implantation or use. Bioburden in-process testing must be 
conducted pursuant to written procedures during the 
manufacturing process of drug products. The United States 
Pharmacopeia (USP) outlines several tests that can be done 
to quantitatively determine the bioburden of non- sterile 
drug products. It is important when conducting these tests 
to ensure that the testing method does not either introduce 
bacteria into the test sample or kill bacteria in the test 
sample. To prepare drug products for testing, they must be 
dissolved in certain substances based on their "physical 
characteristics. For example, a water-soluble drug product 
should be dissolved in "Buffered Sodium Chloride-Peptone 
Solution pH 7.0, Phosphate Buffer Solution pH 7.2, or 
Soybean-Casein Digest Broth. The Membrane-Filtration 
Method and Plate Count Method can be used to measure the 
number of microbes in a sample. In the Membrane-Filtration 
Method, the sample is passed through a membrane filter 
with a pore size of 0.45 micrometers or less. The membrane 
filter is then placed onto Soybean-Casein Digest Agar and 
incubated in order to be able to determine the total aerobic 
microbial count (TAMC).In the Plate Count Method, the 
sample of drug product to be tested and Soybean-Casein 
Digest Broth is poured into a Petri dish. The Petri dish is 
then incubated. The most probable number method (MPN) 
can also be performed for products considered to have a low 
bioburden[clarification needed]. The MPN is considered to 
be one of the least accurate tests. The bioburden 
quantification is expressed in colony forming unit (CFU). 
There are generally established guidelines for the maximum 
CFU that a drug product can contain. Contact plates or sterile 
swabs can also be used to test for microbes on a surface 
when compounding sterile products to ensure compliance 
with USP 797. Bioburden is also associated with biofouling, 
where microbes collect on the surface of a device or inside of 
fan cooled equipment. In healthcare settings, this increases 
the risk of Healthcare-associated infections (HAIs) or 
Hospital-acquired infections as pathogens can be spread 
through contact or through the air to new patients and 
hospital staff. Fan cooled system are generally avoided in 
critical care and operating rooms, thus relying on natural 
convection or liquid cooling to cool devices and equipment. 
These rooms are also required to maintain negative air 
pressure so that air may enter the room, but the air cannot 
exit into other rooms. HEPA filters are also used to collect 
airborne pathogens larger than 0.3 microns.3, 28,  29 
 
Figure 3: Soybean Caesin Digest Media 
5. Sources 
A. Air/Particulate matter 
B. Human handling 
C. Contact with surfaces 
D. Contact with liquids(endotoxins) 
E. Can also come from previous use of a device on 
humans (reusable devices) 
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6. Determining Bioburden 
A. First: Recovery is the best method to extract bioburden 
Factors affecting 
B. Antimicrobials 
C. Device Geometry 
7. Bioburden result reported in CFUs  
Collecting samples for Bioburden 
A. Large and frequent production: 3 lots of 10 for initial 
bioburden 
B. Smaller or infrequent production: 10products 
8. Bioburden Enumeration Testing 
The microbial enumeration test, also called the bioburden 
test or the microbial load test, is performed to monitor the 
microbial content in raw materials, in-process samples, and 
finished product in the pharmaceutical, biological, 
cosmetics, nutritional products, and medical device 
industry. The FDA expects companies to monitor the 
bioburden load in products used for humans and animals. 
The bioburden test can be performed by several methods 
based on the nature of the material tested. The following is 
a list of the extraction methods offered. The extraction 
method is the procedure for removing the microorganisms 
from the product being tested. 
A. Immersion 
B. Flush /Rinse 
C. Surface Sampling 
D. Dilution 
The following is a list of the enumeration methods offered. 
The enumeration method is the procedure used to 
determine the number of viable microorganisms that are 
extracted from the product being tested. 
A. Membrane Filtration 
B. Direct Plating 
C. Most Probable Number(MPN) 
 
 
  
Figure 4: Direct Plate Method and Assembly of Membrane Filtration 
 
The microbial load test should be validated to ensure that 
the method is effective, accurate, and reproducible in 
determining the material’s microbial load in a test article. 
The most suitable methodology should be determined as 
part of method development. Validation will be performed 
with the method that shows the best recovery of organisms 
with no inhibition. Validation is performed per USP/EP for 
Pharmaceutical or Biotechnology products, and AAMI for 
medical devices. Cosmetics are tested per FDA BAM manual. 
MQA can also develop custom bioburden procedures for 
samples that are difficult to test. 
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Figure 5: Microbiological Growth Curve 
Table 2: Overview of Contamination Control 27, 28, 29, 30 
Content Validation Control Monitoring 
Facility Qualification the clean Room area and 
HVAC 
Maintenance of facilities in 
sanitization revision of barriers, 
traffic patterns or air balance 
Environmental monitoring 
HVAC Qualification of the clean room area 
and HVAC system 
Certification and prevention, 
maintenance of system repair of 
HEPA filter 
Environmental monitoring 
Water Qualification of water system Certification and personnel 
monitoring  regular sanitization of 
system 
Environment monitoring of 
water system 
Equipment Qualification of the equipment as 
suitable for its  intended use 
Certification and preventative 
monitoring regular sanitization 
Environmental monitoring 
finished product release 
testing 
Sanitization Validation of cleaning , sanitization 
sporicidal treatments 
Regular cleaning and sanitization of 
facilities and equipment 
Environmental monitoring 
Personnel  Proficiency criteria participation in 
media fills trending data by operator  
Training discipline Personnel monitoring 
trending data by operator 
Process  Process validation Acceptance testing of raw material 
and containers 
In-process bioburden 
monitoring finished product 
release testing 
 
9. Routine Monitoring 
Routine monitoring procedures for the manufacturing 
environment and equipment may involve the following 
methods. 
9.1 Surface testing 
Testing of surfaces may be carried out using swabs, contact 
plates, contact slides or the rapid bioluminescence test. 
Contact plates and slides are designed so that the surface of 
the solid media may be directly applied to the test surface 
and then incubated. Such tests are quick and easy to use, and 
results are directly related to the contact area. The 
disadvantage is that possibly not all organisms will adhere to 
the media, and the plates or slides can be used only on flat 
surfaces. Determining bioburden by use of swabs is 
particularly useful for monitoring irregularly shaped 
equipment and difficult-to-access surfaces. Swabs are 
normally moistened in a liquid medium and then rubbed 
across a predetermined area. The swab may be directly 
applied to agar medium, or the swab may be immersed in 
liquid media, agitated to remove organisms and the TVC 
completed as for liquid testing. Direct application of the 
swab to the agar may not remove all organisms from the 
swab, whereas using an intermediate liquid stage will 
improve recovery of the organisms. Bioluminescence testing 
is especially helpful for examining surface bioburden 
because results are rapidly obtained and will confirm 
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whether cleaning procedures have been carried out 
correctly. This will enable a quick response to any problem 
areas identified, thereby preventing product contamination. 
The test method utilizes the reaction that occurs between 
bacterial adenosine triphosphate (ATP) and firefly 
luciferin/luciferase, resulting in emission of light.  
 
  
Figure 6: Contact Plate Method and Slide Method 
  
Figure 7:  Swab Method and ATP Bioluminescence 
 
9.2 Powders and liquids 
Microbiological testing of powders and liquids can be 
achieved utilizing pour plates, spiral plating/spread plates, 
membrane filtration or the dilution droplet technique of 
Miles and Misra. In the case of water testing, the Most 
Probable Number (MPN) method can also be considered A 
measured amount of powder can be dissolved in either a 
suitable solvent or in liquid culture media. Testing then 
proceeds as for liquid samples. Solvents and powder samples 
may have an inhibitory effect, however. Therefore, suitable 
dilutions or neutralizing agents should be used. For the pour 
plate method, samples of liquid are added to cooled molten 
agar and mixed, and plates are poured. When set, plates are 
incubated at appropriate temperatures and times, and 
colonies are counted. Alternatively, a liquid sample may be 
directly applied to the agar surface, spread and then 
incubated. A smaller sample may be required in order to 
ensure that discrete colonies are cultured and so enable 
accurate counting. Samples may be delivered and spread 
using spiral plating equipment. The number of colonies can 
be related to the volume of suspension delivered and the 
total count calculated. For the Miles and Misra method, a 
series of dilutions are made from the samples. Then 
measured drops are placed on the agar surface. A minimum 
of five separated drops from each dilution is required. Plates 
are allowed to dry and are incubated, and counts are made. 
When large sample volumes are available, particularly as in 
the case of water testing, the MPN method may be used. A 
range of dilutions is made in liquid growth medium. The 
range must be selected so that the lowest dilutions do not 
show microbial growth. Tables have been produced, such as 
those by DeMan, using statistical assessments to determine 
the MPNs of organisms present in the initial sample. In tests 
of chlorinated water, any residual antimicrobial effect of the 
chlorine may be neutralized with sodium thiosulphate. The 
membrane filtration technique utilizes a membrane with a 
sub-micron pore size, large enough to enable large volumes 
to pass under pressure, but small enough to retain bacteria. 
The membrane is then placed onto an agar plate and 
incubated, and colonies are counted. This technique is 
particularly useful when there are low numbers of microbes 
or when there may be interfering substances in the liquid 
sample beingtested.3, 5, 12, 29, 31 
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Figure 8: Pour Plate Method and Spiral Method 
 
Figure 9: Spread Plate Method 
 
9.3 Air Sampling 
Microbiological testing of air samples may be achieved by 
using settle plates or by active air sampling. Agar plates are 
left exposed for a defined period of time in the area under 
test. They are then incubated and colonies are counted. 
Whyte has established that, for a bioburden of 100 cfu per 
m3, a 90 mm diameter plate exposed for an hour will show 
10 or 11 cfu. Active sampling systems are also available. Air 
is drawn into a device for a measured period of time. The 
micro-organisms are deposited onto agar, which is then 
incubated. Types of active air samplers available are slit 
samplers, centrifugal samplers and impaction samplers. The 
cost of equipment and consumables may be high. Membrane 
filtration may also be used. Air samples are passed through a 
sub-micron membrane filter pad for a designated time. The 
membrane is subsequently placed on an agar surface and 
then cultured to determine bacterial numbers present in the 
air sample. In the case of all air sampling techniques, loss of 
viability may occur due to desiccation of the organisms. 
Hence, prolonged sampling times should be avoided.31, 32 
 
9.4 Identification of micro-organism 
On completion of the primary testing, additional tests may 
be required to identify any organisms isolated, in order to 
confirm that none of the prohibited organisms are present. 
A gram stain, coagulase test and oxidase test will indicate 
whether species identification is required. Biochemical 
profiles may be used to identify organisms to species level. 
9.5 Rapid test method  
There are rapid test methods available that may be 
considered for testing materials and product and for 
environmental testing. Rapid test technology obtains 
bioburden measurement by utilizing turbidity, 
bioluminescence, conductance or impedance of preliminary 
testing will determine baseline counts to enable routine test 
limits to be established. When defined, the recommended 
limits must be at a level that will ensure product safety. 
After bioburden limits have been established, routine 
testing programmes can be installed for all stages of the 
manufacturing process. 
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10. Equipments 
All manufacturing equipment, including tote bins, should be 
cleaned and sanitized at regular intervals to a written 
schedule. Cleaning should be microbiologically validate 
dusting surface test methods to ensure the efficacy of the 
cleaning procedures and to ensure that there is no cross-
contamination onto product. 27, 28 
11. Environment 
The manufacturing environment should be controlled to 
minimize microbial contamination and to ensure that pests 
such as rodents, birds and insects do not gain access to any 
manufacturing areas. This is especially important in the 
manufacturing stages after final drying. It is recommended 
that air sampling be regularly conducted, particularly in 
areas where the condoms are most vulnerable to microbial 
contamination, until product has been foiled. 
12. Personnel 
Microbial contamination may also arise from personnel. 
When standing still, a person will normally shed 1,00,000 
particles per minute. Moving may increase this to more than 
one million particles per minute. These particles will contain 
microbes normally present on skin. Coughing, sneezing and 
touching product or equipment will also greatly add to the 
bioburden. Suitable protective clothing and gloved hands will 
give a measure of protection against this contamination. GMP 
training will help to enforce correct handling procedures to 
ensure that contact and cross-contamination between 
personnel and product are minimized. 27, 28 
13. Raw materials 
All raw materials, including water and packaging materials, 
should be tested at regular intervals. Some materials may 
have an inherent antimicrobial effect. If this has been 
confirmed, then monitoring may continue at a much 
reduced rate on these particular materials. 
14. Water 
Water is a major material used during manufacturing, and so 
it must be controlled microbiologically and chemically. Some 
incoming water supplies may contain extremely high 
bioburden levels, particularly in adverse local weather 
conditions such as very heavy rainfall or drought, and must 
be treated before storage. Treatment methods may include 
filtration, reverse osmosis (RO) ultraviolet irradiation (UV) 
or chemical treatment. It should be noted that chemical 
treatment may interfere with production processes and, 
depending on the chemicals used, may also cause adverse 
reactions in personnel. After initial treatment the stored 
water should be kept under controlled conditions to 
minimize any further contamination or growth of micro-
organisms. Additional treatment of water may be necessary 
to produce deionised (DI) or softened water. Many 
microorganisms find favour able conditions for growth on 
the DI resin beds and on RO membranes. It is essential, 
therefore, that the servicing protocols be followed rigorously 
to prevent colonization of the equipment with microbes. If 
UV irradiation is used, monitoring of the system to confirm 
correct UV emission is essential in order to ensure that the 
UV lamps have not become partially obscured and therefore 
ineffective.5, 27, 28 
15. Dipping, stripping and drying 
Dipping lines utilize large volumes of process water, which 
is sometimes re-circulated at certain points of the process. It 
is recommended that there is no recirculation, but, if 
recirculation is necessary, it should be kept to a minimum 
and only re-circulated for short periods of time or for a 
single re-use. 5, 27, 28 
16. Conclusion 
Microbiological testing will confirm whether bioburden is 
being properly controlled under these circumstances. All 
equipment should be regularly monitored, using surface 
testing methods that will confirm the efficacy of cleaning. 
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